I want to make sure that our bio-similars capture a huge market share and help cancer patients around the world, which we are already doing in the developing world because we didn't have access to these drugs. Biocon enjoys a large reputation of giving them high-quality cancer drug.
It's unconscionable that cancer patients get the wrong diagnosis 30 percent of the time and that it takes so long to treat them with appropriate drugs for their cancer.
Because Genentech is a leading developer of cancer therapies, some doctors also fear that the company's pricing plans for Avastin - around $8,800 a month - may encourage other companies to charge more for their own oncology drugs.
Studies show that Avastin can prolong the lives of patients with late-stage breast and lung cancer by several months when the drug is combined with existing therapies.
If China and India were as rich as the United States is today, the market for cancer drugs would be eight times larger than it is now.
I believe that we are going to have a much deeper appreciation of what kinds of abnormalities in cancer cells and in the surrounding cells that feed and respond to cancers are vulnerabilities that will allow us to make better predictions of which kinds of drugs will work to treat these cancers.
Price gouging for drugs that treat cancer in children is simply unconscionable.
I've written and passed laws to give Medicare beneficiaries access to life saving cancer drugs and to ensure that seniors don't have to give up the prospect of a cure when they go into hospice care.
Reducing the price of cancer drugs is a humanitarian move.
